Biotech Values

[orangeone]

More impressed after digesting 8k. While $33M is peanuts for six products, we should ignore upfront altogeher, I would not want MNTA to focus on getting upfront cash anyway. MNTA gets an honest royalty which is in the range of a very good preclinical deal for an innovative product, save that here we are not only in preclinical but we are talking about generics where competition is the base case. So good. And, royalties increase to double, presumably if MNTA finds itself in the lovenox like situation where it can sue to keep others out. High single digit, optionally increased two-fold, is not bad when the time to market is less than the 10+ years which is the rule for innovator products.